Description: The eBioHMb1-1 monoclonal antibody reacts with mouse and rat CD29 (integrin beta 1), a 110-120 kDa member of the beta integrin family expressed by leukocytes, endothelial, smooth muscle and epithelial cells. CD29 binds non-covalently with the alpha integrins CD49a-f to form the VLA-1 through VLA-6 complexes, as well as with CD51. These alpha-beta integrin heterodimers are capable of mediating a variety of cellular responses including adhesion, trafficking, proliferaton and differentiation. All integrins which include CD29 bind to extracellular matrix proteins including collagen, laminin, fibronectin and vitronectin, whereas some CD29-containing integrins can also interact with cellular receptors such as VCAM-1 and MadCAM-1.
Applications Reported: This eBioHMb1-1 (HMb1-1) antibody has been reported for use in flow cytometric analysis, and immunoprecipitation. (Please use Functional Grade purified eBioHMb1-1 (HMb1-1), cat. 16-0291, in functional assays.).
Applications Tested: This eBioHMb1-1 (HMb1-1) antibody has been tested by flow cytometric analysis of mouse spleen, thymus and bone marrow cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
ITGB1 (Integrin Subunit Beta 1, beta1 integrin subunit, GPIIa, CD29) is a 110 kDa cell surface glycoprotein that is widely expressed by a variety of cells including all leucocytes. ITGB1 forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CDa-f) determining the binding properties of beta1 (VLA) integrins. ITGB1 is a cell adhesion molecule appearing on platelets, as the common Beta subunit of the very late activation antigen (VLA), and as a component of various protein complexes binding to extracellular matrix proteins. Decreased expression of ITGB1 correlates with acquiring multidrug resistance of tumor cells in the presence of anti-tumor drug. ITGB1 is up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue. Further, ITGB1 also regulates tissue damage and disease symptoms related to inflammatory bowel disease. Through an ITGB1-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta. More than 8 beta subunits with numerous splice variant isoforms have been identified in mammals. There are two major forms of integrin beta1: beta1A and beta1D, which differ in 13 amino acids. The distribution pattern in adult tissues for integrin beta types are mutually exclusive. Beta1A is present in all tissues, except cardiac and skeletal muscle which express the beta1D variant.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Beta OL; Beta oligodendroglia; CD29; Fibronectin receptor subunit beta; integrin beta 1 (fibronectin receptor beta); Integrin beta-1; Integrin beta1; integrin VLA-4 subunit beta; ITBG1D; VLA-4 subunit beta
Gene Aliases: 4633401G24Rik; AA409975; AA960159; CD29; ENSMUSG00000051907; Fnrb; Gm9863; gpIIa; Itgb1
Molecular Function: integrin